Sugammadex Injectable Product — Competitive Intelligence Brief

Sugammadex Injectable Product (Sugammadex Injectable Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective relaxant binding agent. Area: Anesthesia.

marketed Selective relaxant binding agent Steroidal neuromuscular blocking agents (rocuronium, vecuronium) Anesthesia Small molecule

Target snapshot

Sugammadex Injectable Product (Sugammadex Injectable Product) — Regina Elena Cancer Institute. Sugammadex is a selective relaxant binding agent that encapsulates and inactivates steroidal neuromuscular blocking agents, rapidly reversing neuromuscular blockade.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sugammadex Injectable Product TARGET	Sugammadex Injectable Product	Regina Elena Cancer Institute	marketed	Selective relaxant binding agent	Steroidal neuromuscular blocking agents (rocuronium, vecuronium)
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
sugammadex ED90	sugammadex ED90	Faculdade de Ciências Médicas da Santa Casa de São Paulo	marketed	Selective relaxant binding agent	Rocuronium and vecuronium (steroidal neuromuscular blocking agents)
Sugammadex Injection [Bridion]	Sugammadex Injection [Bridion]	University Health Network, Toronto	marketed	Selective relaxant binding agent	Rocuronium and vecuronium (steroidal neuromuscular blocking agents)
Sugammadex injection	Sugammadex injection	University of California, Irvine	marketed	Selective relaxant binding agent	Steroidal neuromuscular blocking agents (rocuronium, vecuronium, pancuronium)
sugammadex 10 min after position change	sugammadex 10 min after position change	Korea University Guro Hospital	marketed	Selective relaxant binding agent	Rocuronium and vecuronium (neuromuscular blocking agents)
Placebo to sugammadex	Placebo to sugammadex	Merck Sharp & Dohme LLC	phase 3	Selective relaxant binding agent	Rocuronium and other steroidal neuromuscular blocking agents

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective relaxant binding agent class)

1. Faculdade de Ciências Médicas da Santa Casa de São Paulo · 1 drug in this class
2. Korea University Guro Hospital · 1 drug in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. Regina Elena Cancer Institute · 1 drug in this class
5. University Health Network, Toronto · 1 drug in this class
6. University of California, Irvine · 1 drug in this class